Compare iShares Self-Driving EV and Tech (IDRV) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Mesoblast Limited — how do they compare? iShares Self-Driving EV and Tech trades at $37.18, while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Mesoblast Limited is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| IDRV | MESO | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $45.48 | $20.96 |
52-Week Low | $34.49 | $12.88 |
Market Cap | — | $2.21B |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $37.18, down 0.51% today, with a bullish technical signal from moving averages and key indicators like the ADX suggesting a strong trend. Support levels are firm near $35–$37, while resistance sits at $38–$39. Recent news highlights rising global EV sales, with growth in Europe and China, though U.S. adoption lags. The company has a dividend scheduled for June 2026.
The outlook for IDRV is cautiously optimistic, driven by sector tailwinds from EV adoption and regulatory support. Key risks include competitive pressures from Chinese automakers and sensitivity to fuel price volatility. Analyst sentiment is mixed, with technical strength offset by fundamental data gaps. Investors should monitor upcoming earnings for margin trends and guidance updates.
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
